An Experimental Study Of Prevention Effect Of The Somatostatin Analogue (Octreotide) On The Growth And Trans-portal Vein Metastasis Of The Mice Bearing Hepatocellular Carcinoma

Objective: To evaluate whether octreotide could act the antitumor and antimetastasis effect ,and the mechanism of that.Method: First section.thirty orthotopic transplantation of the KM mouse bearing hepatocellular carcinoma were randomized into 3 groups:1.control.(NS.ip.qd) 2.1ow density(50ug /kg octreotide.ip.qd) 3.high density(100 g /kg octreotide ip.qd).Total mouse were sacrificed two weeks after administration.then 1.detect the longest and perpendicular dimension(a,b) of the tumor,the volume of the tumor was calculated occording to the formula:V=l/2ab2. 2.the pre-treatment and the post-treatment weight of mice. 3.immunohistochemistry was used to detect MVD and apoptosis.Second section:0.03ml(about 3 l06) H22 hepatocellular carcinoma cells from mice abdomen inoculating 5 days were injected into KM mice spleen envelope as model of trans-portal vein metastasis. Twenty mouse were randomized into 2 groups. l.control(NS.ip.qd). 2.treatment(100 g /kg octreotide .ip.qd).Total mouse were sacrificed ten days after administration.metastasis grading according :o standard made by Gao Jing.Result: 1 .First section .the tumor growth of every treatment groups was significantly different from the control.(p<0.05).So were the MVD and AI.(p<0.05).there was no significantly difference between treatment groups and control group.(p>0.05).but the ratio of whole prevention effect in treatment group was very low.Conclusion: Somatostatin analogue octreotide can act antitumor effect. The mechanism is through inducing apoptosis of the tumor cell and inhibition of angiogenesis.Octreotide can prevent H22 metastasis from portal vein. The machnism is still under study.